样式: 排序: IF: - GO 导出 标记为已读
-
Prognostic values of tumor size and location in early stage endometrial cancer patients who received radiotherapy. J. Gynecol. Oncol. (IF 3.9) Pub Date : 2024-04-09 Shuning Jiao, Lichun Wei, Lijuan Zou, Tiejun Wang, Ke Hu, Fuquan Zhang, Xiaorong Hou
To investigate the correlation between tumor size, tumor location, and prognosis in patients with early-stage endometrial cancer (EC) receiving adjuvant radiotherapy.
-
Cost-effectiveness of pembrolizumab plus chemotherapy for advanced endometrial cancer. J. Gynecol. Oncol. (IF 3.9) Pub Date : 2024-04-08 Gengwei Huo, Ying Song, Peng Chen
To assess the cost-effectiveness of pembrolizumab in combination with chemotherapy compared to chemotherapy alone, based on the results of the NRG-GY018 trial, in patients with advanced or recurrent endometrial cancer (EC), stratified by mismatch repair-deficient (dMMR) and mismatch repair-proficient (pMMR) subgroups.
-
Cost-effectiveness of atezolizumab plus chemotherapy for advanced/recurrent endometrial cancer. J. Gynecol. Oncol. (IF 3.9) Pub Date : 2024-04-03 Gengwei Huo, Ying Song, Peng Chen
This study assessed the cost-effectiveness of atezolizumab in combination with chemotherapy for patients with advanced or recurrent endometrial cancer (EC) from the U.S. payer's perspective.
-
Comprehensive characterization of genomic features and clinical outcomes following targeted therapy and secondary cytoreductive surgery in OCCC: a single center experience. J. Gynecol. Oncol. (IF 3.9) Pub Date : 2024-03-29 Silvana Talisa Wijaya, Natalie Yl Ngoi, Jerold Wz Loh, Tuan Zea Tan, Diana Lim, Irfan Sagir Khan, Yee Liang Thian, Alexa Lai, Bertrand Wl Ang, Pearl Tong, Joseph Ng, Jeffrey Jh Low, Arunachalam Ilancheran, Siew Eng Lim, Yi Wan Lim, David Sp Tan
Ovarian clear cell carcinoma (OCCC) is associated with chemoresistance. Limited data exists regarding the efficacy of targeted therapies such as immune checkpoint inhibitors (ICI) and bevacizumab, and the role of secondary cytoreductive surgery (SCS).
-
QL1604 plus paclitaxel-cisplatin/carboplatin in patients with recurrent or metastatic cervical cancer: an open-label, single-arm, phase II trial. J. Gynecol. Oncol. (IF 3.9) Pub Date : 2024-03-29 Cheng Fang, Yun Zhou, Yanling Feng, Liping He, Jinjin Yu, Yuzhi Li, Mei Feng, Mei Pan, Lina Zhao, Dihong Tang, Xiumin Li, Buzhen Tan, Ruifang An, Xiaohui Zheng, Meimei Si, Baihui Zhang, Lingyan Li, Xiaoyan Kang, Qi Zhou, Jihong Liu
QL1604 is a highly selective, humanized monoclonal antibody against programmed death protein 1. We assessed the efficacy and safety of QL1604 plus chemotherapy as first-line treatment in patients with advanced cervical cancer.
-
SLAMF7 predicts prognosis and correlates with immune infiltration in serous ovarian carcinoma. J. Gynecol. Oncol. (IF 3.9) Pub Date : 2024-03-29 Yalong Deng, Lu Zhang, Changyuan Dai, Yan Xu, Qiyu Gan, Jingxin Cheng
Signaling lymphocytic activation molecule family members (SLAMFs) play a critical role in immune regulation of malignancies. This study aims to investigate the prognostic value and function of SLAMFs in ovarian cancer (OC).
-
A retrospective study of dose-dense paclitaxel and carboplatin plus bevacizumab as first-line treatment of advanced epithelial ovarian cancer. J. Gynecol. Oncol. (IF 3.9) Pub Date : 2024-03-26 Hiromi Komazaki, Kazuaki Takahashi, Hiroshi Tanabe, Yuichi Shoburu, Misato Kamii, Akina Tsuda, Motoaki Saito, Kyosuke Yamada, Hirokuni Takano, Hirofumi Michimae, Aikou Okamoto
This study compared the effectiveness, safety, and tolerability of dose-dense paclitaxel and carboplatin plus bevacizumab (ddTC+Bev) with ddTC for advanced ovarian cancer.
-
Abnormal p53 expression is associated with poor outcomes in grade I or II, stage I, endometrioid carcinoma: a retrospective single-institute study. J. Gynecol. Oncol. (IF 3.9) Pub Date : 2024-03-22 Yu-Wei Chang, Hsiao-Li Kuo, Tzu-Chien Chen, Jessica Chen, Ling Lim, Kung-Liahng Wang, Jen-Ruei Chen
The Cancer Genome Atlas study revealed an association between copy-number high (p53 abnormal) genetic mutation and poor prognosis in endometrial cancer in 2013. This retrospective study investigated outcomes in patients with abnormal p53 expression and stage I, low-grade endometrial endometrioid carcinoma (EEC).
-
Patient and clinician priorities for information on treatment outcomes for advanced ovarian cancer: a Delphi exercise. J. Gynecol. Oncol. (IF 3.9) Pub Date : 2024-03-21 Kathryn Baxter, Heather Agnew, Jennie Morgan, Cathrine Holland, Darren Flynn, Richard Edmondson
Patients with advanced ovarian cancer face a range of treatment options, and there is unwarranted variation in treatment decision-making between UK providers. Decision support tools that produce data on treatment outcomes as a function of individual patient characteristics, would help both patients and clinicians to make informed, preference- and values-based choices. However, data on treatment outcomes
-
Mirvetuximab soravtansine in platinum-resistant recurrent ovarian cancer with high folate receptor-alpha expression: a cost-effectiveness analysis. J. Gynecol. Oncol. (IF 3.9) Pub Date : 2024-03-21 Youwen Zhu, Yinxin Lin, Kun Liu, Hong Zhu
Mirvetuximab soravtansine (MIRV), a new antibody-drug conjugate, versus the investigator's choice of chemotherapy (IC) was the first treatment to demonstrate benefits for progression-free and overall survival in platinum-resistant recurrent ovarian cancer (PROC) with high folate receptor-alpha (high-FRα) expression. Efficacy, safety, and economic effectiveness make MIRV the new standard of care for
-
Chemotherapy response score no longer predicts survival outcomes in high-grade serous ovarian cancer patients with BRCA mutation and/or maintenance therapy. J. Gynecol. Oncol. (IF 3.9) Pub Date : 2024-03-18 Young Joo Lee, Yoon Kyung Shin, Nae Ry Kim, Se Ik Kim, Yoo-Young Lee, Jeong-Yeol Park, Jae-Weon Kim, Hyun-Woong Cho, Jung-Yun Lee
We aimed to revalidate the chemotherapy response score (CRS) system as a prognostic factor for ovarian cancer patients with breast cancer gene (BRCA) mutations or those receiving frontline poly-ADP ribose polymerase (PARP) inhibitors or bevacizumab as maintenance therapy.
-
Evaluation of clinical usefulness of HPV-16 and HPV-18 genotyping for cervical cancer screening. J. Gynecol. Oncol. (IF 3.9) Pub Date : 2024-03-15 Eun Hye Cho, Min-Seung Park, Hee-Yeon Woo, Hyosoon Park, Min-Jung Kwon
High-risk human papillomavirus (HR-HPV) infection is a leading cause of cervical cancer, of which human papillomavirus (HPV)-16 and HPV-18 account for about 70% of cases. Since HPV infection is common, it is important to focus on the HPV genotypes that pose the highest risk for effective cervical cancer screening. In this study, we evaluated the clinical usefulness of HPV-16/HPV-18 genotyping for cervical
-
Lymphadenectomy in clinically early epithelial ovarian cancer and survival analysis (LILAC): a Gynecologic Oncology Research Investigators Collaboration (GORILLA-3002) retrospective study. J. Gynecol. Oncol. (IF 3.9) Pub Date : 2024-03-12 Eun Jung Yang, A Jin Lee, Woo Yeon Hwang, Suk-Joon Chang, Hee Seung Kim, Nam Kyeong Kim, Yeorae Kim, Tae Wook Kong, Eun Ji Lee, Soo Jin Park, Joo-Hyuk Son, Dong Hoon Suh, Dong Hee Son, Seung-Hyuk Shim
This study aimed to evaluate the therapeutic role of lymphadenectomy in patients surgically treated for clinically early-stage epithelial ovarian cancer (EOC).
-
Influence of cancer in pregnancy on obstetric and neonatal outcomes: an observational retrospective cohort study. J. Gynecol. Oncol. (IF 3.9) Pub Date : 2024-03-11 Xuan Huang, Chen Zhang, Jialei Zhu, Yueyan Li, Jing Tang
The study aimed to review the oncological characteristics and treatment of pregnancy-associated cancers and analyze the obstetric and neonatal outcomes to provide evidence-based recommendations for reproductive function preservation, oncological treatment, and obstetric management.
-
Intraoperative frozen section pathology of vaginal margin in radical hysterectomy on the prognosis and quality of life for patients with IB2-IIA2 cervical cancer: study protocol for a multicenter randomized controlled trial. J. Gynecol. Oncol. (IF 3.9) Pub Date : 2024-03-11 Yu Liu, Weijuan Xin, Ping Wang, Mei Ji, Xiaoqing Guo, Yunyan Ouyang, Dong Zhao, Keqin Hua
Several risk factors have been identified that compromise the treatment outcome in patients with early-to-mid-stage cervical cancer (CC) who are primarily treated with radical surgery. However, there is no report on the impact of intraoperative frozen pathology examination of vaginal margins on the prognosis of patients with CC. This study aimed to conduct a randomized controlled trial (RCT) to determine
-
Hormone replacement therapy in gynecological cancer survivors and BRCA mutation carriers: a MITO group survey. J. Gynecol. Oncol. (IF 3.9) Pub Date : 2024-03-04 Innocenza Palaia, Giuseppe Caruso, Violante Di Donato, Camilla Turetta, Antonella Savarese, Giorgia Perniola, Roberta Gallo, Andrea Giannini, Vanda Salutari, Giorgio Bogani, Federica Tomao, Diana Giannarelli, Gabriella Gentile, Angela Musella, Ludovico Muzii, Sandro Pignata
Early iatrogenic menopause in gynecological cancer survivors and BRCA mutation (BRCAm) carriers undergoing risk-reducing salpingo-oophorectomy (RRSO) is a major health concern. Hormone replacement therapy (HRT) is the most effective remedy, but remains underused in clinical practice. The Multicenter Italian Trials in Ovarian cancer and gynecologic malignancies (MITO) group promoted a national survey
-
TET3-mediated DNA demethylation modification activates SHP2 expression to promote endometrial cancer progression through the EGFR/ERK pathway. J. Gynecol. Oncol. (IF 3.9) Pub Date : 2024-02-29 Fen Xue, Lifen Liu, Xueqiang Tao, Weipei Zhu
Src homology phosphotyrosin phosphatase 2 (SHP2) has been implicated in the progression of several cancer types. However, its function in endometrial cancer (EC) remains unclear. Here, we report that the ten-eleven translocation 3 (TET3)-mediated DNA demethylation modification is responsible for the oncogenic role of SHP2 in EC and explore the detailed mechanism.
-
Cost-effectiveness analysis of hospital treatment volume and survival outcomes in endometrial cancer in Japan. J. Gynecol. Oncol. (IF 3.9) Pub Date : 2024-02-26 Hiroko Machida, Koji Matsuo, Takahiro Higashi, Daisuke Aoki, Takayuki Enomoto, Aikou Okamoto, Hidetaka Katabuchi, Satoru Nagase, Masaki Mandai, Nobuo Yaegashi, Wataru Yamagami, Mikio Mikami
Hospital treatment volume affects survival in patients with endometrial cancer; notably, initial treatment at high-volume centers improves survival outcomes. Our study assessed the effect of hospital treatment volume on cost-effectiveness and survival outcomes in patients with endometrial cancer in Japan.
-
CDK1 promotes the phosphorylation of KIFC1 to regulate the tumorgenicity of endometrial carcinoma. J. Gynecol. Oncol. (IF 3.9) Pub Date : 2024-02-26 Xi Lin, Yingying He, Yiming Liu, Huihao Zhou, Xiaomin Xu, Jingui Xu, Kening Zhou
This study aims to clarify the mechanical action of cyclin-dependent protein kinase 1 (CDK1) in the development of endometrial carcinoma (EMCA), which may be associated with the phosphorylation of kinesin family member C1 (KIFC1) and further activate the PI3K/AKT pathway.
-
Comparison of outcomes of laparotomic and minimally invasive radical hysterectomy in women with early-stage cervical cancer. J. Gynecol. Oncol. (IF 3.9) Pub Date : 2024-02-23 Shu-Han Chang, Kuan-Gen Huang, Lan-Yan Yang, Yu-Bin Pan, Chyong-Huey Lai, Hung-Hsueh Chou
This study compared the outcomes of laparotomic radical hysterectomy (LRH) and minimally invasive radical hysterectomy (MISRH) in patients with early-stage cervical cancer.
-
The efficacy of the levonorgestrel intrauterine system versus oral megestrol acetate in treating atypical endometrial hyperplasia: a superior randomized controlled trial. J. Gynecol. Oncol. (IF 3.9) Pub Date : 2024-02-22 Amr A Alnemr, Ola A Harb, Hytham Atia
To compare the efficacy of the levonorgestrel intrauterine system (LNG-IUS) versus megestrol acetate (MA) in inducing complete regression among women with atypical endometrial hyperplasia (AEH) who declined hysterectomy.
-
Clinical practice guidelines for cervical cancer: the Korean Society of Gynecologic Oncology guidelines. J. Gynecol. Oncol. (IF 3.9) Pub Date : 2024-02-13 Ji Geun Yoo, Sung Jong Lee, Eun Ji Nam, Jae Hong No, Jeong Yeol Park, Jae Yun Song, So-Jin Shin, Bo Seong Yun, Sung Taek Park, San-Hui Lee, Dong Hoon Suh, Yong Beom Kim, Keun Ho Lee
This fifth revised version of the Korean Society of Gynecologic Oncology practice guidelines for the management of cervical cancer incorporates recent research findings and changes in treatment strategies based on version 4.0 released in 2020. Each key question was developed by focusing on recent notable insights and crucial contemporary issues in the field of cervical cancer. These questions were
-
A predictive model for lymph node metastasis using tumor location in presumed early-stage endometrioid endometrial cancer patients. J. Gynecol. Oncol. (IF 3.9) Pub Date : 2024-01-22 Tae-Wook Kong, Jayoun Kim, Junghoe Kim, Jimin Lee, Jeeyeon Kim, Joo-Hyuk Son, Suk-Joon Chang
The aim of this study was to identify high- and low-risk subgroups of patients with lymph node (LN) metastasis in presumed early-stage endometrioid endometrial cancer (EC) patients.
-
The new 2023 FIGO staging system for endometrial cancer: what is different from the previous 2009 FIGO staging system? J. Gynecol. Oncol. (IF 3.9) Pub Date : 2024-01-22 Kyung Hee Han, NohHyun Park, Maria Lee, Cheol Lee, Hyojin Kim
The International Federation of Gynecology and Obstetrics committee modified the endometrial cancer (EC) staging system based on the histopathological feature and molecular profile. The aim is to evaluate the clinical implications of the new 2023 system compared with the previous 2009 system.
-
Clinical implications of the superficial uterine vein pattern for the dissection of the anterior layer of the vesicouterine ligament in radical hysterectomy. J. Gynecol. Oncol. (IF 3.9) Pub Date : 2024-01-22 Atsushi Fusegi, Hiroyuki Kanao, Mayumi Kamata, Shogo Nishino, Akiko Abe, Makiko Omi, Hidetaka Nomura
To describe anatomic patterns of the superficial uterine vein (sUV) and assess their association with aspects of the dissection procedure of the anterior layer of the vesicouterine ligament (aVUL) by retrospectively reviewing surgical videos.
-
Analysis of East Asia Subgroup in Study 309/KEYNOTE-775: Lenvatinib plus pembrolizumab versus treatment of physician's choice chemotherapy in patients with previously treated advanced or recurrent endometrial cancer. J. Gynecol. Oncol. (IF 3.9) Pub Date : 2024-01-19 Kan Yonemori, Keiichi Fujiwara, Kosei Hasegawa, Mayu Yunokawa, Kimio Ushijima, Shiro Suzuki, Ayumi Shikama, Shinichiro Minobe, Tomoka Usami, Jae-Weon Kim, Byoung-Gie Kim, Peng-Hui Wang, Ting-Chang Chang, Keiko Yamamoto, Shirong Han, Jodi McKenzie, Robert J Orlowski, Takuma Miura, Vicky Makker, Yong Man Kim
In the global phase 3 Study 309/KEYNOTE-775 (NCT03517449) at the first interim analysis, lenvatinib+pembrolizumab significantly improved progression-free survival (PFS), overall survival (OS), and objective response rate (ORR) versus treatment of physician's choice chemotherapy (TPC) in patients with previously treated advanced/recurrent endometrial cancer (EC). This exploratory analysis evaluated
-
Diagnostic significance and predictive efficiency of metabolic risk score for fertility-sparing treatment in patients with atypical endometrial hyperplasia and early endometrial carcinoma. J. Gynecol. Oncol. (IF 3.9) Pub Date : 2024-01-19 Xingchen Li, Yiqin Wang, Jiaqi Wang, Jingyi Zhou, Jianliu Wang
This study aims to assess the impact of the metabolic risk score (MRS) on both the time to achieve complete remission (CR) of fertility-sparing treatments for atypical endometrial hyperplasia (AEH) and early EC patients.
-
Evolving standards and future directions for systemic therapies in cervical cancer. J. Gynecol. Oncol. (IF 3.9) Pub Date : 2024-01-15 Daniel Jia Ming Ang, Jack Junjie Chan
Several groundbreaking clinical trials with the potential to transform the management paradigm of both locally advanced and persistent, recurrent, or metastatic cervical cancers have been presented in 2023. This review describes the reported data from INTERLACE and KEYNOTE-A18 in the locally advanced setting, as well as BEATcc, innovaTV 301 and DESTINY-PanTumor02 for advanced disease. The practice
-
PARPis response and outcome of ovarian cancer patients with BRCA1/2 germline mutation and a history of breast cancer. J. Gynecol. Oncol. (IF 3.9) Pub Date : 2024-01-12 Hua Yuan, Lin Xiu, Ning Li, Yifan Li, Lingying Wu, Hongwen Yao
The aim of this study was to determine the poly (ADP-ribose) polymerase inhibitors (PARPis) response and outcome of ovarian cancer (OC) patients with BRCA1/2 germline mutation and a history of breast cancer (BC).
-
Confirmation of the utility of the CA-125 elimination rate (KELIM) as an indicator of the chemosensitivity in advanced-stage ovarian cancer in a "real-life setting". J. Gynecol. Oncol. (IF 3.9) Pub Date : 2024-01-08 Lilian van Wagensveld, Olivier Colomban, Maaike A van der Aa, Gilles Freyer, Gabe S Sonke, Roy F P M Kruitwagen, Benoit You
The modeled CA-125 ELIMination rate constant K (KELIM) has been validated as a marker of response to chemotherapy in >12,000 patients with advanced epithelial ovarian carcinoma (EOC) treated in first-line setting enrolled in >12 clinical trials. Patient KELIM is calculable online https://www.biomarker-kinetics.org/presentation. The objective was to investigate the prognostic value of KELIM in a large
-
Practice guidelines for management of uterine corpus cancer in Korea: a Korean Society of Gynecologic Oncology consensus statement. J. Gynecol. Oncol. (IF 3.9) Pub Date : 2024-01-05 Ju-Hyun Kim, Dae-Yeon Kim, Junhwan Kim, Joseph J Noh, Woo Yeon Hwang, Min-Hyun Baek, Min Chul Choi, Won Duk Joo, Yong Jae Lee, Dong Hoon Suh, Yong Beom Kim
The Korean Society of Gynecologic Oncology (KSGO) had been making an effort to standardize and enhance the quality of domestic uterine corpus cancer treatment by developing updated clinical practice guidelines in 2021. The KSGO revised the guidelines based on a literature search using 4 key elements: Population, Intervention, Comparison, and Outcome framework. These elements include the evaluation
-
Prevention of symptomatic pulmonary embolism for gynecologic malignancies with preoperative asymptomatic venous thromboembolism: GOTIC-VTE trial. J. Gynecol. Oncol. (IF 3.9) Pub Date : 2024-01-01 Yoshifumi Takahashi, Hiroyuki Fujiwara, Kouji Yamamoto, Masashi Takano, Morikazu Miyamoto, Kosei Hasegawa, Maiko Miwa, Toyomi Satoh, Hiroya Itagaki, Takashi Hirakawa, Mayuyo Mori-Uchino, Tomonori Nagai, Yoshinobu Hamada, Soichi Yamashita, Hiroko Yano, Tomoyasu Kato, Keiichi Fujiwara, Mitsuaki Suzuki
In Japan, perioperative prophylaxis of pulmonary embolism (PE) in gynecologic cancer patients with preoperative asymptomatic venous thromboembolism (VTE) has not been well established yet. The GOTIC-VTE trial was a prospective, multi-center, single-arm clinical trial to investigate the prevention of postoperative symptomatic PE onset by seamless anticoagulant therapy from the preoperative period to
-
Cerebral infarction caused by Trousseau syndrome associated with cervical cancer. J. Gynecol. Oncol. (IF 3.9) Pub Date : 2024-01-01 Motoko Kanno, Mayu Yunokawa, Atsushi Fusegi, Akiko Abe, Hidetaka Nomura, Hiroyuki Kanao
The combination of cancer and hypercoagulable states is often called Trousseau syndrome. In particular, cerebral infarction caused by Trousseau syndrome is reported to have a poor prognosis. In gynecology, there are many reports of ovarian cancer and a few of uterine cancer. Since there has been no comprehensive report of Trousseau syndrome in cervical cancer, we aimed to summarize Trousseau syndrome
-
Can surgery boost the survival benefit of chemoradiotherapy in T1b1-T2a1 stage cervical cancer with lymph node metastasis? A population-based study. J. Gynecol. Oncol. (IF 3.9) Pub Date : 2023-12-29 Yiwei Wang, You Lyu, Xiaoxia Che, Jing Li, Weiwei Feng
This study aimed to determine whether surgery followed by adjuvant chemoradiotherapy has superior survival outcomes for node-positive patients with T1b1-T2a1 stage cervical cancer compared with those who undergo chemoradiation.
-
Preoperative laboratory parameters associated with deep vein thrombosis in patients with ovarian cancer: retrospective analysis of 3,147 patients in a single institute. J. Gynecol. Oncol. (IF 3.9) Pub Date : 2023-12-29 Hyoeun Shim, Yeon Jee Lee, Ji Hyun Kim, Myong Cheol Lim, Dong-Eun Lee, Sang Yoon Park, Sun-Young Kong
Patients with ovarian cancer have a high risk of developing thrombosis. We aimed to investigate laboratory parameters associated with deep vein thrombosis (DVT) in patients treated for ovarian cancer.
-
Development and validation of a novel scoring system to predict the risk of uterine perforation during intracavitary brachytherapy for cervical cancer. J. Gynecol. Oncol. (IF 3.9) Pub Date : 2023-12-29 Ezhil Sindhanai M Parvath, Neenu Oliver John, Arvind Sathyamurthy, Jeba Karunya Ramireddy, Thomas Samuel Ram
To develop and validate a novel scoring system for predicting the risk of uterine perforation during brachytherapy (BT) in cervical cancer patients and to stratify patients based on this score to guide the use of ultrasound guidance during BT.
-
Clinical guidelines for ovarian cancer: the Korean Society of Gynecologic Oncology guidelines. J. Gynecol. Oncol. (IF 3.9) Pub Date : 2023-12-27 Banghyun Lee, Suk-Joon Chang, Byung Su Kwon, Joo-Hyuk Son, Myong Cheol Lim, Yun Hwan Kim, Shin-Wha Lee, Chel Hun Choi, Kyung Jin Eoh, Jung-Yun Lee, Dong Hoon Suh, Yong Beom Kim
Since the latest practice guidelines for ovarian cancer were developed by the Korean Society of Gynecologic Oncology (KSGO) in 2021, many studies have examined the efficacy and safety of various treatments for epithelial ovarian cancer (EOC). Therefore, the need to develop recommendations for EOC treatments has been raised. This study searched the literature using 4 key items and the Population, Intervention
-
Trends in the incidence and survival outcomes of endometrial cancer in Korea: a nationwide population-based cohort study. J. Gynecol. Oncol. (IF 3.9) Pub Date : 2023-12-19 Seung-Hyuk Shim, Jiwon Lim, Ji Hyun Kim, Yeon Jee Lee, Hyeong In Ha, Myong Cheol Lim, Young-Joo Won
To evaluate trends in the incidence and survival outcomes of endometrial cancer (EC) based on the year of diagnosis, stage, age, and histologic types.
-
Efficacy of fertility-sparing treatment with LNG-IUS is associated with different ProMisE subtypes of endometrial carcinoma or atypical endometrial hyperplasia. J. Gynecol. Oncol. (IF 3.9) Pub Date : 2023-12-18 Xiaofeng Lv, Lili Guo, Changyu Wang
To determine whether proactive molecular risk classifier for endometrial cancer (ProMisE) could be used to assess the prognosis of patients with atypical endometrial hyperplasia (AEH) or early-stage endometrial cancer (EC) treated with levonorgestrel-releasing intrauterine system (LNG-IUS).
-
Implementation rate and related factors of confirmatory tests following an abnormal Pap smear: a nationwide study from the National Health Insurance. J. Gynecol. Oncol. (IF 3.9) Pub Date : 2023-12-18 Hyeongsu Kim, Kyeong Yeon Kim, Dasom Kim, Jong Ha Hwang
This study aims to investigate the implementation rate and influencing factors of confirmatory tests for women with abnormal cervical cytology results in the Korean nationwide cervical cancer screening program.
-
Impact of adjuvant treatment on survival in patients with 2023 FIGO stage IIC endometrial cancer: a retrospective analysis from two tertiary centers in Korea and Taiwan. J. Gynecol. Oncol. (IF 3.9) Pub Date : 2023-12-12 Yoo-Young Lee, Yen-Ling Lai, Myeong-Seon Kim, Koping Chang, Hyun-Soo Kim, Wen-Fang Cheng, Yu-Li Chen
In early-stage endometrial cancer, aggressive histologic types (grade 3 endometrioid, serous, clear cell, carcinosarcomas, undifferentiated, mixed, and other unusual types) are associated with an increased risk of distant metastases and worse survival. However, the optimal adjuvant treatment for these patients remains controversial. The present study investigated the outcomes of different adjuvant
-
Supragastric lesser sac: an insidious site for surgical exploration during the debulking surgery in advanced ovarian cancer. J. Gynecol. Oncol. (IF 3.9) Pub Date : 2023-12-11 Yulian Chen, Zhuozhen Sun, Songqi Cai, Yan Hu, Rong Jiang, Libing Xiang, Rongyu Zang
Metastases in the supragastric lesser sac (SGLS) are not only occult but are also barriers to complete resection of ovarian cancer. We describe a cohort of patients with SGLS disease undergoing debulking surgery.
-
The automatic diagnosis artificial intelligence system for preoperative magnetic resonance imaging of uterine sarcoma. J. Gynecol. Oncol. (IF 3.9) Pub Date : 2023-12-07 Yusuke Toyohara, Kenbun Sone, Katsuhiko Noda, Kaname Yoshida, Shimpei Kato, Masafumi Kaiume, Ayumi Taguchi, Ryo Kurokawa, Yutaka Osuga
Magnetic resonance imaging (MRI) is efficient for the diagnosis of preoperative uterine sarcoma; however, misdiagnoses may occur. In this study, we developed a new artificial intelligence (AI) system to overcome the limitations of requiring specialists to manually process datasets and a large amount of computer resources.
-
Japan Society of Gynecologic Oncology 2022 guidelines for uterine cervical neoplasm treatment. J. Gynecol. Oncol. (IF 3.9) Pub Date : 2023-11-27 Manabu Seino, Satoru Nagase, Hideki Tokunaga, Wataru Yamagami, Yoichi Kobayashi, Tsutomu Tabata, Masanori Kaneuchi, Yasuyuki Hirashima, Hitoshi Niikura, Kiyoshi Yoshino, Kazuhiro Takehara, Tsukasa Baba, Hidetaka Katabuchi, Mikio Mikami
The Japan Society of Gynecologic Oncology (JSGO) Guidelines 2022 for the Treatment of Uterine Cervical Cancer are revised from the 2017 guideline. This guideline aimed to provide standard care for cervical cancer, indicate appropriate current treatment methods for cervical cancer, minimize variances in treatment methods among institutions, improve disease prognosis and treatment safety, reduce the
-
Impact of peritoneal vaginoplasty combined with radical hysterectomy on the quality of sexual life for patients with early-stage cervical cancer: trial protocol for a multi-center superiority randomized controlled trial. J. Gynecol. Oncol. (IF 3.9) Pub Date : 2023-11-27 Shimin Yang, Yan Ding, Huaifang Li, Sufang Wu, Weiwei Feng, Yudong Wang, Xipeng Wang, Keqin Hua
Radical hysterectomy (RH) is commonly used to treat early-stage cervical cancer in women of childbearing age and sexual dysfunction due to postoperative vaginal shortening is a major concern. The impact of intraoperative vaginoplasty on prognosis and quality of sexual life in patients with early-stage cervical cancer remains controversial and lacks high-level evidence. However, there are few reports
-
Sentinel node mapping in endometrial cancer. J. Gynecol. Oncol. (IF 3.9) Pub Date : 2023-11-13 Giorgio Bogani, Andrea Giannini, Enrico Vizza, Violante Di Donato, Francesco Raspagliesi
Nodal status is one of the most important prognostic factors for patients with apparent early stage endometrial cancer. The role of retroperitoneal staging in endometrial cancer is controversial. Nodal status provides useful prognostic data, and allows to tailor the need of postoperative treatments. However, two independent randomized trials showed that the execution of (pelvic) lymphadenectomy increases
-
Evaluation of Secondary Cytoreduction Surgery in Platinum-Resistant Ovarian Cancer Patients Within Three-Line Recurrent: A Multicenter, Randomized Controlled Study. J. Gynecol. Oncol. (IF 3.9) Pub Date : 2023-10-30 Tingting Chen, Junfen Xu, Bairong Xia, Hui Wang, Yuanming Shen
Epithelial ovarian cancer is the leading cause of death among gynecological malignancies. Platinum resistance remains a dilemma and bottleneck in treatment, and salvage chemotherapy has limited effectiveness. Recently, the role of secondary cytoreductive surgery (SCS) in patients with platinum-resistant recurrent ovarian cancer (ROC) has caused attention especially in patients with oligometastases
-
Study of neoadjuvant chemotherapy in advanced malignant ovarian germ cell tumors at a tertiary center in western India. J. Gynecol. Oncol. (IF 3.9) Pub Date : 2023-10-23 Abhilash Vasanth,Shilpa M Patel,Ruchi Arora,Chetana D Parekh,Pariseema Dave,Bijal M Patel,Priyanka Vemanamandhi
OBJECTIVE To study clinical characters and outcomes in patients of malignant ovarian germ cell tumor (MOGCT) undergoing surgery following neoadjuvant chemotherapy (NACT). METHODS Retrospective study of patients undergoing surgery following NACT for MOGCT at our institute. Platinum based chemotherapy was given in all patients in NACT. RESULTS Between March 2013 and February 2023, 30 patients had surgery
-
Robotic or laparoscopic pelvic exenteration for gynecological malignancies: feasible options to open surgery. J. Gynecol. Oncol. (IF 3.9) Pub Date : 2023-10-19 Laura Dudus,Corina Minciuna,Stefan Tudor,Monica Lacatus,Bogdan Stefan,Catalin Vasilescu
OBJECTIVE To acknowledge that minimally invasive pelvic exenteration is a feasible alternative to open surgery and potentially identify prediction factors for patient outcome. METHODS The study was designed as a retrospective single team analysis of 12 consecutive cases, set between January 2008 and January 2022. RESULTS Six anterior and 6 total pelvic exenterations were performed. A 75% of cases were
-
Cervical screening among Chinese females in the era of HPV vaccination: a population-based survey on screening uptake and regular screening following an 18-year organized screening program. J. Gynecol. Oncol. (IF 3.9) Pub Date : 2023-10-18 Horace Cw Choi,Kathy Leung,Joseph T Wu
OBJECTIVE China has a substantial disease burden of cervical cancer. To further understand preventive measures for reducing cervical cancer in China, this study aimed to correlate screening attendance and regular screening with human papillomavirus (HPV) vaccination among Chinese females. METHODS This prospective questionnaire-based survey recruited Chinese females aged 25 or above in Hong Kong by
-
A machine learning-based prediction model of pelvic lymph node metastasis in women with early-stage cervical cancer. J. Gynecol. Oncol. (IF 3.9) Pub Date : 2023-10-18 Kamonrat Monthatip,Chiraphat Boonnag,Tanarat Muangmool,Kittipat Charoenkwan
OBJECTIVE To develop a novel machine learning-based preoperative prediction model for pelvic lymph node metastasis (PLNM) in early-stage cervical cancer by combining the clinical findings and preoperative computerized tomography (CT) of the whole abdomen and pelvis. METHODS Patients diagnosed with International Federation of Gynecology and Obstetrics stage IA2-IIA1 squamous cell carcinoma, adenocarcinoma
-
Cisplatin-induced PANDAR-Chemo-EVs contribute to a more aggressive and chemoresistant ovarian cancer phenotype through the SRSF9-SIRT4/SIRT6 axis. J. Gynecol. Oncol. (IF 3.9) Pub Date : 2023-10-18 Hao Wang,Yinuo Li,Yanan Wang,Xiumin Shang,Zhongxin Yan,Shengli Li,Wei Bao
OBJECTIVE We previously elucidated that long non-coding RNA Promoter of CDKN1A Antisense DNA damage Activated RNA (PANDAR) as a p53-dependent oncogene to promote cisplatin resistance in ovarian cancer (OC). Intriguingly, high level of p53-independent PANDAR was found in cisplatin-resistant patients with p53 mutation. Here, our study probed the new roles and the underlying mechanisms of PANDAR in p53-mutant
-
Regularity of cervical cancer screening in Korea: analysis using national public data for 12 years. J. Gynecol. Oncol. (IF 3.9) Pub Date : 2023-10-16 Jong-Yeup Kim,Jeeyoung Hong,Juhee Yoon,Jinsol Park,Tae-Hyun Kim
OBJECTIVE To assess the frequency of regular uptake of national cervical cancer screening (CCS) program and identify associated factors among Korean women. METHODS This study is a fundamental investigation that employs openly accessible public data of Korea through secondary data analysis. A cohort of 4,663 women from the 2007-2012 Korean National Health and Nutrition Examination Survey, was followed
-
Feasibility of laparoscopic Visceral-Peritoneal Debulking (L-VPD) in patients with stage III-IV ovarian cancer: the ULTRA-LAP trial pilot study. J. Gynecol. Oncol. (IF 3.9) Pub Date : 2023-10-16 Roberto Tozzi,Marco Noventa,Carlo Saccardi,Giulia Spagnol,Orazio De Tommasi,Davide Coldebella,Matteo Marchetti
OBJECTIVE A non-randomized prospective clinical trial (ULTRA-LAP) was registered to test safety, side effects and efficacy of laparoscopic Visceral-Peritoneal Debulking (L-VPD) in patients with stage III-IV ovarian cancer (OC). A pilot study was designed to identify which OC patients are suitable to undergo L-VPD. METHODS Between March 2016 and October 2021, all consecutive patients with OC underwent
-
Adjuvant carboplatin and paclitaxel with "sandwich" method radiotherapy for stage III or IV endometrial cancer: long-term follow-up at a single-institution. J. Gynecol. Oncol. (IF 3.9) Pub Date : 2023-10-16 Anu Chinnadurai,Daniel Breadner,Ziad Baloush,Ana Elisa Lohmann,Morgan Black,David D'Souza,Stephen Welch
OBJECTIVE To evaluate disease-free survival (DFS) and overall survival (OS) associated with adjuvant carboplatin and paclitaxel chemotherapy interposed with radiation for advanced endometrial cancer. METHODS This is a cohort study of adult women with stage III or IV endometrial cancer treated at a single institution, between April 2002 and October 2017. Tumor and treatment characteristics were recorded
-
Erratum: Closing the gap for cervical cancer research in Vietnam: current perspectives and future opportunities: a report from the 5th Gynecologic Cancer InterGroup (GCIG) Cervical Cancer Research Network (CCRN) Education Symposium. J. Gynecol. Oncol. (IF 3.9) Pub Date : 2023-09-18 Ngoc T H Phan, Quy T Tran, Nhan P T Nguyen, Hang T Nguyen, Linh D N Tran, Viet C Pham, Katherine Bennett, Adriana Chávez-Blanco, Marie Plante, Fabrice R Lecuru, Dong Hoon Suh, Remi Nout, David S P Tan
This corrects the article on p. e88 in vol. 34, PMID: 37668081.
-
Predictive factors of surgical complications after pelvic exenteration for gynecological malignancies: a large single-institution experience. J. Gynecol. Oncol. (IF 3.9) Pub Date : 2023-09-11 Lucia Tortorella, Cintoni Marco, Matteo Loverro, Conte Carmine, Eleonora Persichetti, Nicolò Bizzarri, Costantini Barbara, Santullo Francesco, Nazario Foschi, Valerio Gallotta, Giacomo Avesani, Vito Chiantera, Alfredo Ercoli, Francesco Fanfani, Anna Fagotti, Maria Cristina Mele, Stefano Restaino, Salvatore Gueli Alletti, Giovanni Scambia, Giuseppe Vizzielli
To evaluate pre-operative predictors of early (<30 days) severe complications (grade Dindo 3+) in patients with gynecological malignancy submitted to pelvic exenteration (PE).
-
Feasibility, accuracy and acceptability of self-sampled human papillomavirus testing using careHPV in Cambodia: a cross-sectional study. J. Gynecol. Oncol. (IF 3.9) Pub Date : 2023-09-11 Sovanara Hang, Rei Haruyama, Kyna Uy, Noriko Fujita, Tadashi Kimura, Kanal Koum, Kei Kawana
Self-sampled human papillomavirus (HPV) testing is a potential option for cervical cancer screening, but research is scarce in Cambodia. We evaluated the feasibility, accuracy, and acceptability of self-sampled HPV testing using careHPV.
-
Comparison of immediate germline sequencing and multi-step screening for Lynch syndrome detection in high-risk endometrial and colorectal cancer patients. J. Gynecol. Oncol. (IF 3.9) Pub Date : 2023-09-05 An-Shine Chao, Angel Chao, Chyong-Huey Lai, Chiao-Yun Lin, Lan-Yan Yang, Shih-Cheng Chang, Ren-Chin Wu
Lynch syndrome (LS) is a hereditary cancer predisposition syndrome with a significantly increased risk of colorectal and endometrial cancers. Current standard practice involves universal screening for LS in patients with newly diagnosed colorectal or endometrial cancer using a multi-step screening protocol (MSP). However, MSP may not always accurately identify LS cases. To address this limitation,
-
Optimal number of neoadjuvant chemotherapy cycles prior to interval debulking surgery in advanced epithelial ovarian cancer: a systematic review and meta-analysis of progression-free survival and overall survival. J. Gynecol. Oncol. (IF 3.9) Pub Date : 2023-09-05 Camelia Alexandra Coada, Giulia Dondi, Gloria Ravegnini, Stella Di Costanzo, Marco Tesei, Enrico Fiuzzi, Marco Di Stanislao, Susanna Giunchi, Claudio Zamagni, Alessandro Bovicelli, Patrizia Hrelia, Sabrina Angelini, Pierandrea De Iaco, Anna Myriam Perrone
Neoadjuvant chemotherapy (NACT) represents a treatment option in patients with advanced epithelial ovarian cancer (AEOC) who are not good candidates for primary debulking surgery. Usually, 3 cycles of chemotherapy before surgery have been considered the best option for patient survival, although quite often some patients receive more than 3 cycles. The aim of this systematic review and meta-analysis